

Antitrypanosomal Therapy for Chronic Chagas' Disease

New England Journal of Medicine

364, 2527-2534

DOI: [10.1056/nejmct1014204](https://doi.org/10.1056/nejmct1014204)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Ipilimumab plus Dacarbazine in Melanoma. <i>New England Journal of Medicine</i> , 2011, 365, 1256-1258.	27.0	12
2	Boron-based drugs as antiprotozoals. <i>Current Opinion in Infectious Diseases</i> , 2011, 24, 586-592.	3.1	50
3	Antitrypanosomal Therapy for Chronic Chagas' Disease. <i>New England Journal of Medicine</i> , 2011, 365, 1258-1259.	27.0	10
5	Triatomine Infestation in Guatemala: Spatial Assessment after Two Rounds of Vector Control. <i>American Journal of Tropical Medicine and Hygiene</i> , 2012, 86, 446-454.	1.4	22
6	Chagas disease in the immunosuppressed host. <i>Current Opinion in Infectious Diseases</i> , 2012, 25, 450-457.	3.1	94
8	Pharmacological Characterization, Structural Studies, and In Vivo Activities of Anti-Chagas Disease Lead Compounds Derived from Tipifarnib. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4914-4921.	3.2	50
9	Therapy of Chagas Disease: Implications for Levels of Prevention. <i>Journal of Tropical Medicine</i> , 2012, 2012, 1-10.	1.7	28
10	Prognostic Significance of Circulating Levels of Hepatocyte Growth Factor in Patients with Chagas Disease and Idiopathic Dilated Cardiomyopathy. <i>Cardiology</i> , 2012, 121, 240-246.	1.4	7
11	Diagnosis and management of Chagas disease and cardiomyopathy. <i>Nature Reviews Cardiology</i> , 2012, 9, 576-589.	13.7	277
12	Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects. <i>Expert Review of Vaccines</i> , 2012, 11, 1043-1055.	4.4	117
13	Chagas Heart Disease. <i>Cardiology in Review</i> , 2012, 20, 53-65.	1.4	90
14	The TGF- β 2 Pathway as an Emerging Target for Chagas Disease Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 613-621.	4.7	46
15	Antitrypanosomal and antioxidant properties of 4-hydroxycoumarins derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 5569-5573.	2.2	48
16	Analogues of Fenarimol Are Potent Inhibitors of <i>Trypanosoma cruzi</i> and Are Efficacious in a Murine Model of Chagas Disease. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 4189-4204.	6.4	58
17	Taiwaniaquinoid and abietane quinone derivatives with trypanocidal activity against <i>T. cruzi</i> and <i>Leishmania</i> spp.. <i>Parasitology International</i> , 2012, 61, 405-413.	1.3	17
18	Emerging Parasitic Infections in Transplantation. <i>Current Infectious Disease Reports</i> , 2012, 14, 642-649.	3.0	7
19	Improved Proteomic Approach for the Discovery of Potential Vaccine Targets in <i>Trypanosoma cruzi</i> . <i>Journal of Proteome Research</i> , 2012, 11, 237-246.	3.7	49
20	Chagasic cardiomyopathy, from acute to chronic: is this mediated by host susceptibility factors?. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2012, 106, 521-527.	1.8	29

#	ARTICLE	IF	CITATIONS
21	The United States <i>Trypanosoma cruzi</i> Infection Study: evidence for vector-borne transmission of the parasite that causes Chagas disease among United States blood donors. <i>Transfusion</i> , 2012, 52, 1922-1930.	1.6	145
22	Mechanisms of <i>Trypanosoma cruzi</i> persistence in Chagas disease. <i>Cellular Microbiology</i> , 2012, 14, 634-643.	2.1	133
23	Parasitic Infections in Solid Organ Transplant Recipients. <i>Infectious Disease Clinics of North America</i> , 2013, 27, 395-427.	5.1	48
24	Novel 3-nitro-1 <i>H</i> -1,2,4-triazole-based piperazines and 2-amino-1,3-benzothiazoles as antichagasic agents. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 6600-6607.	3.0	37
25	The Assassin: Chagas Cardiomyopathy. <i>American Journal of Medicine</i> , 2013, 126, 864-867.	1.5	2
26	Design or screening of drugs for the treatment of Chagas disease: what shows the most promise?. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 1479-1489.	5.0	25
28	Treatment of Chagas' disease with itraconazole: electrocardiographic and parasitological conditions after 20 years of follow-up. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2164-2169.	3.0	31
29	Heart Transplantation for Chagas Cardiomyopathy in the United States. <i>American Journal of Transplantation</i> , 2013, 13, 3262-3268.	4.7	55
30	Rational Development of 4-Aminopyridyl-Based Inhibitors Targeting <i>Trypanosoma cruzi</i> CYP51 as Anti-Chagas Agents. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7651-7668.	6.4	43
31	Use of an enzyme-linked immunosorbent assay that utilizes the Tc13Tul antigen of <i>Trypanosoma cruzi</i> to monitor patients after treatment with benznidazole. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 76, 197-205.	1.8	6
32	VNI Cures Acute and Chronic Experimental Chagas Disease. <i>Journal of Infectious Diseases</i> , 2013, 208, 504-511.	4.0	91
33	Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of <i>Trypanosoma cruzi</i> . <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 1756-1763.	3.0	27
34	Novel 1 <i>H</i> -1,2,3-, 2 <i>H</i> -1,2,3-, 1 <i>H</i> -1,2,4- and 4 <i>H</i> -1,2,4-triazole derivatives: a patent review (2008 - 2011). <i>Expert Opinion on Therapeutic Patents</i> , 2013, 23, 319-331.	5.0	57
35	Chagas disease (American trypanosomiasis) in Mexico: An update. <i>Acta Tropica</i> , 2013, 127, 126-135.	2.0	81
36	Synthesis of coumarin-chalcone hybrids and evaluation of their antioxidant and trypanocidal properties. <i>MedChemComm</i> , 2013, 4, 993.	3.4	66
37	Chagas Disease. <i>Journal of the American College of Cardiology</i> , 2013, 62, 767-776.	2.8	329
38	The use of steroids to prevent cutaneous reactions to benznidazole in patients with Chagas disease. <i>Pathogens and Global Health</i> , 2013, 107, 157-160.	2.3	10
39	Barriers to Treatment Access for Chagas Disease in Mexico. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2488.	3.0	81

#	ARTICLE	IF	CITATIONS
40	Combined treatment with benznidazole and allopurinol in mice infected with a virulent <i>Trypanosoma cruzi</i> isolate from Nicaragua. <i>Parasitology</i> , 2013, 140, 1225-1233.	1.5	15
41	Synthesis and evaluation of antioxidant and trypanocidal properties of a selected series of coumarin derivatives. <i>Future Medicinal Chemistry</i> , 2013, 5, 1911-1922.	2.3	26
42	Novel 3-nitro-1 <i>H</i> -1,2,4-triazole-based compounds as potential anti-Chagasic drugs: <i>in vivo</i> studies. <i>Future Medicinal Chemistry</i> , 2013, 5, 1763-1776.	2.3	32
43	A Case of Vertical Transmission of Chagas Disease Contracted via Blood Transfusion in Canada. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2013, 24, 32-34.	1.9	16
44	Optical Absorption of the Antitrypanocidal Drug Benznidazole in Water. <i>Molecules</i> , 2014, 19, 4145-4156.	3.8	10
45	Reversible Cysteine Protease Inhibitors Show Promise for a Chagas Disease Cure. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1167-1178.	3.2	74
46	Nucleoside triphosphate diphosphohydrolase1 (TcNTPDase-1) gene expression is increased due to heat shock and in infective forms of <i>Trypanosoma cruzi</i> . <i>Parasites and Vectors</i> , 2014, 7, 463.	2.5	9
47	American Trypanosomiasis. , 2014, , 622-630.e1.		1
48	Health Policies to Control Chagas Disease Transmission in European Countries. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3245.	3.0	86
49	Profile of <i>Trypanosoma cruzi</i> Infection in a Tropical Medicine Reference Center, Northern Italy. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3361.	3.0	17
50	Biomarkers in <i>Trypanosoma cruzi</i> -Infected and Uninfected Individuals with Varying Severity of Cardiomyopathy in Santa Cruz, Bolivia. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3227.	3.0	31
51	Absence of calcium-independent phospholipase A2 β impairs platelet-activating factor production and inflammatory cell recruitment in <i>Trypanosoma cruzi</i> -infected endothelial cells. <i>Physiological Reports</i> , 2014, 2, e00196.	1.7	10
52	Bioluminescence imaging of chronic <i>Trypanosoma cruzi</i> infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection. <i>Cellular Microbiology</i> , 2014, 16, 1285-1300.	2.1	210
53	Considerations for Screening Live Kidney Donors for Endemic Infections: A Viewpoint on the UNOS Policy. <i>American Journal of Transplantation</i> , 2014, 14, 1003-1011.	4.7	49
54	Clinical Reasoning: A 32-year-old woman with right-sided numbness and word-finding difficulties. <i>Neurology</i> , 2014, 83, e98-102.	1.1	0
55	Epidemiological Aspects of Chagas Disease - a Review. <i>Journal of Ancient Diseases & Preventive Remedies</i> , 2014, 02, .	0.2	4
56	Chagas disease in solid organ and heart transplantation. <i>Current Opinion in Infectious Diseases</i> , 2014, 27, 418-424.	3.1	58
57	Randomized Trial of Posaconazole and Benznidazole for Chronic Chagas' Disease. <i>New England Journal of Medicine</i> , 2014, 370, 1899-1908.	27.0	499

#	ARTICLE	IF	CITATIONS
58	Toxic and therapeutic effects of Nifurtimox and Benznidazol on <i>Trypanosoma cruzi</i> ex vivo infection of human placental chorionic villi explants. <i>Acta Tropica</i> , 2014, 132, 112-118.	2.0	27
59	Cerebral trypanosomiasis in a renal transplant recipient. <i>Transplant Infectious Disease</i> , 2014, 16, 813-817.	1.7	14
60	Posaconazole versus Benznidazole for Chronic Chagas' Disease. <i>New England Journal of Medicine</i> , 2014, 371, 965-966.	27.0	22
61	Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents. <i>European Journal of Medicinal Chemistry</i> , 2014, 87, 79-88.	5.5	39
62	Structural Basis for Rational Design of Inhibitors Targeting <i>Trypanosoma cruzi</i> Sterol 14 α -Demethylase: Two Regions of the Enzyme Molecule Potentiate Its Inhibition. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 6704-6717.	6.4	35
63	Triazolopyrimidine compounds containing first-row transition metals and their activity against the neglected infectious Chagas disease and leishmaniasis. <i>European Journal of Medicinal Chemistry</i> , 2014, 85, 526-534.	5.5	54
64	A Clinical Adverse Drug Reaction Prediction Model for Patients with Chagas Disease Treated with Benznidazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6371-6377.	3.2	39
65	Neglected Parasitic Infections in the United States: Chagas Disease. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014, 90, 814-818.	1.4	116
66	<i>Trypanosoma cruzi</i> Meningoencephalitis in a Patient with Acquired Immunodeficiency Syndrome. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014, 91, 84-85.	1.4	23
67	Diversity-Oriented Synthesis Yields a New Drug Lead for Treatment of Chagas Disease. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 149-153.	2.8	35
68	Chagas disease in the 21st Century: a public health success or an emerging threat?. <i>Parasite</i> , 2014, 21, 11.	2.0	133
70	The use of posaconazole against Chagas disease. <i>Current Opinion in Infectious Diseases</i> , 2015, 28, 397-407.	3.1	48
71	A Family Cluster of Chagas Disease Detected through Selective Screening of Blood Donors: A Case Report and Brief Review. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2015, 26, 157-161.	1.9	7
72	Integrated control of Chagas disease for its elimination as public health problem - A Review. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2015, 110, 289-298.	1.6	29
73	Adipose Tissue-Derived Mesenchymal Stromal Cells Protect Mice Infected with <i>Trypanosoma cruzi</i> from Cardiac Damage through Modulation of Anti-parasite Immunity. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003945.	3.0	26
74	Novel Gallate Triphenylphosphonium Derivatives with Potent Antichagasic Activity. <i>PLoS ONE</i> , 2015, 10, e0136852.	2.5	30
75	Trypanosomiasis and leishmaniasis. , 0, , 1302-1312.		0
76	<i>Trypanosoma</i> Species (American Trypanosomiasis, Chagas' Disease). , 2015, , 3108-3115.e2.		13

#	ARTICLE	IF	CITATIONS
77	Synthesis and biological evaluation of quinones derived from natural product komaroviquinone as anti-Trypanosoma cruzi agents. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2967-2971.	2.2	13
78	Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes. Cell, 2015, 161, 1252-1265.	28.9	135
79	Drugs for Protozoal Infections Other Than Malaria. , 2015, , 510-518.e3.		4
80	The Epidemiology, Clinical Manifestations, and Management of Chagas Heart Disease. Clinical Cardiology, 2015, 38, 565-569.	1.8	76
81	A New Era for Chagas Disease Drug Discovery?. Progress in Medicinal Chemistry, 2015, 54, 185-230.	10.4	36
82	Novel 3-Nitrotriazole-Based Amides and Carbinols as Bifunctional Antichagasic Agents. Journal of Medicinal Chemistry, 2015, 58, 1307-1319.	6.4	46
83	Chagasâ€™ Disease. New England Journal of Medicine, 2015, 373, 456-466.	27.0	625
84	Access to Care for Chagas Disease in the United States: A Health Systems Analysis. American Journal of Tropical Medicine and Hygiene, 2015, 93, 108-113.	1.4	94
85	Prevalence of Chagas Disease in Latin-American Migrants Living in Europe: A Systematic Review and Meta-analysis. PLoS Neglected Tropical Diseases, 2015, 9, e0003540.	3.0	262
86	Controlled but not cured: Structural processes and explanatory models of Chagas disease in tropical Bolivia. Social Science and Medicine, 2015, 145, 7-16.	3.8	21
87	Toxic Profile of Benznidazole in Patients with Chronic Chagas Disease: Risk Factors and Comparison of the Product from Two Different Manufacturers. Antimicrobial Agents and Chemotherapy, 2015, 59, 6125-6131.	3.2	76
88	Gene-deleted live-attenuated Trypanosoma cruzi parasites as vaccines to protect against Chagas disease. Expert Review of Vaccines, 2015, 14, 681-697.	4.4	27
89	Circulating Serum Markers and QRS Scar Score in Chagas Cardiomyopathy. American Journal of Tropical Medicine and Hygiene, 2015, 92, 39-44.	1.4	32
90	Bug Smash, Bug Splash: A Case Report of an Unusual Transmission of American Trypanosomiasis with a Brief Review of the Literature. American Journal of Case Reports, 2016, 17, 993-996.	0.8	0
91	Natural Sesquiterpene Lactones as Potential Trypanocidal Therapeutic Agents: A Review. Natural Product Communications, 2016, 11, 1934578X1601101.	0.5	6
92	Dendritic Cells: A Double-Edged Sword in Immune Responses during Chagas Disease. Frontiers in Microbiology, 2016, 7, 1076.	3.5	28
93	The Prevalence of Atrial Fibrillation and Conduction Abnormalities in Chagasâ€™ Disease: A Meta-Analysis. Journal of Cardiovascular Electrophysiology, 2016, 27, 161-169.	1.7	20
94	A Critical Assessment of Officially Reported Chagas Disease Surveillance Data in Mexico. Public Health Reports, 2016, 131, 59-66.	2.5	8

#	ARTICLE	IF	CITATIONS
95	Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine. <i>Scientific Reports</i> , 2016, 6, 27458.	3.3	18
96	Clomipramine and Benznidazole Act Synergistically and Ameliorate the Outcome of Experimental Chagas Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3700-3708.	3.2	22
97	Novel cruzipain inhibitors for the chemotherapy of chronic Chagas disease. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 91-95.	2.5	26
98	Putting Infection Dynamics at the Heart of Chagas Disease. <i>Trends in Parasitology</i> , 2016, 32, 899-911.	3.3	83
99	Parasites After Hematopoietic Stem Cell or Solid Organ Transplantation. , 2016, , 795-820.		2
100	Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. <i>Nature</i> , 2016, 537, 229-233.	27.8	325
101	Host and parasite genetics shape a link between <i>Trypanosoma cruzi</i> infection dynamics and chronic cardiomyopathy. <i>Cellular Microbiology</i> , 2016, 18, 1429-1443.	2.1	78
102	Systematic Review and Meta-analysis of the Pharmacokinetics of Benznidazole in the Treatment of Chagas Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 7035-7042.	3.2	12
104	Parasites. <i>Microbiology Spectrum</i> , 2016, 4, .	3.0	29
105	Congenital and perinatally-acquired infections in resource-constrained settings. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 845-861.	4.4	13
106	Nitroheterocyclic drugs cure experimental <i>Trypanosoma cruzi</i> infections more effectively in the chronic stage than in the acute stage. <i>Scientific Reports</i> , 2016, 6, 35351.	3.3	72
107	Phenotypic Screening <i>In Vitro</i> of Novel Aromatic Amidines against <i>Trypanosoma cruzi</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4701-4707.	3.2	23
109	Synthesis and biological evaluation of quinoxaline di- N -oxide derivatives with in vitro trypanocidal activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 903-906.	2.2	16
110	Total Artificial Heart as Bridge to Heart Transplantation in Chagas Cardiomyopathy: Case Report. <i>Transplantation Proceedings</i> , 2016, 48, 279-281.	0.6	11
111	New approach towards the synthesis of selenosemicarbazones, useful compounds for Chagas' disease. <i>European Journal of Medicinal Chemistry</i> , 2016, 109, 107-113.	5.5	15
112	Structural analysis and molecular docking of trypanocidal aryloxy-quinones in trypanothione and glutathione reductases: a comparison with biochemical data. <i>Journal of Biomolecular Structure and Dynamics</i> , 2017, 35, 1785-1803.	3.5	15
113	Long-term comparative pharmacovigilance of orally transmitted Chagas disease: first report. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 319-325.	4.4	18
114	Overview and recent advances in the treatment of neuroblastoma. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 369-386.	2.4	286

#	ARTICLE	IF	CITATIONS
115	Heart Transplantation for Chagas Cardiomyopathy. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 597-603.	0.6	44
116	Antiparasitic Treatment Induces an Improved CD8+ T Cell Response in Chronic Chagasic Patients. <i>Journal of Immunology</i> , 2017, 198, 3170-3180.	0.8	43
117	Pharmacokinetics and Tissue Distribution of Benznidazole after Oral Administration in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	45
118	Molecular modeling and structure-activity relationships for a series of benzimidazole derivatives as cruzain inhibitors. <i>Future Medicinal Chemistry</i> , 2017, 9, 641-657.	2.3	18
119	Cross-sectional, descriptive study of Chagas disease among citizens of Bolivian origin living in Munich, Germany. <i>BMJ Open</i> , 2017, 7, e013960.	1.9	31
120	The Trypomastigote Small Surface Antigen from <i>Trypanosoma cruzi</i> Improves Treatment Evaluation and Diagnosis in Pediatric Chagas Disease. <i>Journal of Clinical Microbiology</i> , 2017, 55, 3444-3453.	3.9	16
121	Cell therapies for Chagas disease. <i>Cytotherapy</i> , 2017, 19, 1339-1349.	0.7	10
122	Pharmacist intervention in patients receiving treatment for Chagas disease: An emerging challenge for non-endemic countries. <i>Infection, Disease and Health</i> , 2017, 22, 219-226.	1.1	2
123	Addressing the Challenges of Chagas Disease. <i>Infectious Diseases in Clinical Practice</i> , 2017, 25, 118-125.	0.3	14
124	Molecular mechanisms of cardiac electromechanical remodeling during Chagas disease: Role of TNF and TGF- β 2. <i>Trends in Cardiovascular Medicine</i> , 2017, 27, 81-91.	4.9	22
126	Protozoan Diseases: Chagas Disease. , 2017, , 70-78.		0
127	Association of caspase-1 polymorphisms with Chagas cardiomyopathy among individuals in Santa Cruz, Bolivia. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2017, 50, 516-523.	0.9	6
128	Experimental and Clinical Treatment of Chagas Disease: A Review. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 97, 1289-1303.	1.4	212
129	Trypanothione Reductase and Superoxide Dismutase as Current Drug Targets for <i>Trypanosoma cruzi</i> : An Overview of Compounds with Activity against Chagas Disease. <i>Current Medicinal Chemistry</i> , 2017, 24, 1066-1138.	2.4	43
130	Linalool, a <i>Piper aduncum</i> essential oil component, has selective activity against <i>Trypanosoma cruzi</i> trypomastigote forms at 4°C. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2017, 112, 131-139.	1.6	34
131	Chagas Disease. , 2017, , 371-381.		1
132	<i>Trypanosoma</i> Species (<i>Trypanosomiasis</i>). , 2018, , 1366-1373.e2.		0
133	From Lemongrass to Ivermectin: Ethnomedical Management of Chagas Disease in Tropical Bolivia. <i>Medical Anthropology: Cross Cultural Studies in Health and Illness</i> , 2018, 37, 236-252.	1.2	15

#	ARTICLE	IF	CITATIONS
134	¿Quiénes se beneficia actualmente del tratamiento etiológico de la enfermedad de Chagas?. Enfermedades Infecciosas Y Microbiología Clínica, 2018, 36, 395-396.	0.5	1
135	Novel Therapies for Relapsed and Refractory Neuroblastoma. Children, 2018, 5, 148.	1.5	34
136	Diagnosis and Management of Chagas Cardiomyopathy in the United States. Current Cardiology Reports, 2018, 20, 131.	2.9	13
137	Trypanocidal activity of copaiba oil and kaurenoic acid does not depend on macrophage killing machinery. Biomedicine and Pharmacotherapy, 2018, 103, 1294-1301.	5.6	19
138	Recombinant Enolase of <i>Trypanosoma cruzi</i> as a Novel Vaccine Candidate against Chagas Disease in a Mouse Model of Acute Infection. Journal of Immunology Research, 2018, 2018, 1-14.	2.2	16
139	Biological evaluation and structure-activity relationships of imidazole-based compounds as antiprotozoal agents. European Journal of Medicinal Chemistry, 2018, 156, 53-60.	5.5	19
140	Hematologic Aspects of Parasitic Diseases. , 2018, , 2278-2303.e6.		3
141	Impact of benznidazole treatment on the functional response of <i>Trypanosoma cruzi</i> antigen-specific CD4+CD8+ T cells in chronic Chagas disease patients. PLoS Neglected Tropical Diseases, 2018, 12, e0006480.	3.0	20
142	Who currently benefits from the aetiological treatment for Chagas disease?. Enfermedades Infecciosas Y Microbiología Clínica (English Ed), 2018, 36, 395-396.	0.3	0
143	Heart transplant outcomes in patients with Chagas cardiomyopathy in the United States. Clinical Transplantation, 2018, 32, e13279.	1.6	19
144	Nanocarriers for effective delivery of benznidazole and nifurtimox in the treatment of chagas disease: A review. Acta Tropica, 2019, 198, 105080.	2.0	28
145	Nifurtimox Inhibits the Progression of Neuroblastoma <i>in vivo</i> . Journal of Cancer, 2019, 10, 2194-2204.	2.5	6
146	Detection of <i>Trypanosoma cruzi</i> by PCR in adults with chronic Chagas disease treated with nifurtimox. PLoS ONE, 2019, 14, e0221100.	2.5	11
147	A behavioral design approach to improving a Chagas disease vector control campaign in Peru. BMC Public Health, 2019, 19, 1272.	2.9	15
148	Proposed multidimensional framework for understanding Chagas disease healthcare barriers in the United States. PLoS Neglected Tropical Diseases, 2019, 13, e0007447.	3.0	33
149	Benzimidazole inhibitors of the major cysteine protease of <i>Trypanosoma brucei</i> . Future Medicinal Chemistry, 2019, 11, 1537-1551.	2.3	7
150	Discovery and Genetic Validation of Chemotherapeutic Targets for Chagas' Disease. Frontiers in Cellular and Infection Microbiology, 2018, 8, 439.	3.9	21
151	A therapeutic preconceptional vaccine against Chagas disease: A novel indication that could reduce congenital transmission and accelerate vaccine development. PLoS Neglected Tropical Diseases, 2019, 13, e0006985.	3.0	26

#	ARTICLE	IF	CITATIONS
152	Infections in Kidney and Pancreas Transplantation. , 2019, , 73-109.		1
153	Progression of Baseline Electrocardiogram Abnormalities in Chagas Patients Undergoing Antitrypanosomal Treatment. Open Forum Infectious Diseases, 2019, 6, ofz012.	0.9	8
154	Chagas Cardiomyopathy in Latin America Review. Current Cardiology Reports, 2019, 21, 8.	2.9	28
155	Translating Chagasic dilating cardiomyopathy to surgical therapies: An under published global challenge. SAGE Open Medicine, 2019, 7, 205031211989592.	1.8	1
156	Exoproteome profiling of Trypanosoma cruzi during amastigogenesis early stages. PLoS ONE, 2019, 14, e0225386.	2.5	6
157	Understanding Structure–Activity Relationships for Trypanosomal Cysteine Protease Inhibitors by Simulations and Free Energy Calculations. Journal of Chemical Information and Modeling, 2019, 59, 137-148.	5.4	17
158	Trypanosomes. , 2019, , .		0
159	The effect of benznidazole dose among the efficacy outcome in the murine animal model. A quantitative integration of the literature. Acta Tropica, 2020, 201, 105218.	2.0	7
160	Foregut Surgery. , 2020, , .		2
161	Hit-to-lead optimization of novel 2-alkylaminomethylquinoline derivatives as anti-chagas agents. European Journal of Medicinal Chemistry, 2020, 186, 111877.	5.5	4
162	The Surgical Management of Parasitic Diseases. , 2020, , .		2
163	Short-course Benznidazole treatment to reduce Trypanosoma cruzi parasitic load in women of reproductive age (BETTY): a non-inferiority randomized controlled trial study protocol. Reproductive Health, 2020, 17, 128.	3.1	16
164	Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection). The Cochrane Library, 2020, 12, CD004102.	2.8	4
165	Chagas cardiomyopathy and heart failure: From epidemiology to treatment. Revista Portuguesa De Cardiologia (English Edition), 2020, 39, 279-289.	0.2	1
166	Extent of polymorphism and selection pressure on the <i>Trypanosoma cruzi</i> vaccine candidate antigen Tc24. Evolutionary Applications, 2020, 13, 2663-2672.	3.1	11
167	Population pharmacokinetics and biodistribution of benznidazole in mice. Journal of Antimicrobial Chemotherapy, 2020, 75, 2213-2221.	3.0	6
168	Chagas disease in the United Kingdom: A review of cases at the Hospital for Tropical Diseases London 1995–2018. The current state of detection of Chagas disease in the UK. Travel Medicine and Infectious Disease, 2020, 36, 101760.	3.0	9
169	Chagas cardiomyopathy and heart failure: From epidemiology to treatment. Revista Portuguesa De Cardiologia, 2020, 39, 279-289.	0.5	19

#	ARTICLE	IF	CITATIONS
170	Chagas Disease: Epidemiology and Barriers to Treatment. American Journal of Medicine, 2020, 133, 1262-1265.	1.5	50
171	The current drug discovery landscape for trypanosomiasis and leishmaniasis: Challenges and strategies to identify drug targets. Drug Development Research, 2022, 83, 225-252.	2.9	47
172	Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II superiority clinical trial. Trials, 2020, 21, 328.	1.6	30
173	Knocking Down TcNTPDase-1 Gene Reduces in vitro Infectivity of Trypanosoma cruzi. Frontiers in Microbiology, 2020, 11, 434.	3.5	5
174	A proportion of CD4+ T cells from patients with chronic Chagas disease undergo a dysfunctional process, which is partially reversed by benznidazole treatment. PLoS Neglected Tropical Diseases, 2021, 15, e0009059.	3.0	9
175	Virtual Screening Based on QSAR and Molecular Docking of Possible Inhibitors Targeting Chagas CYP51. Journal of Chemistry, 2021, 2021, 1-15.	1.9	8
176	In vitro susceptibility of Trypanosoma cruzi discrete typing units (DTUs) to benznidazole: A systematic review and meta-analysis. PLoS Neglected Tropical Diseases, 2021, 15, e0009269.	3.0	24
178	Structure Activity Relationship of N-Substituted Phenylhydrazolones Against Trypanosoma cruzi Amastigotes. Frontiers in Chemistry, 2021, 9, 608438.	3.6	1
179	Risk of COVID-19 in Chagas Disease Patients: What Happen with Cardiac Affectations?. Biology, 2021, 10, 411.	2.8	7
180	Nanocarrier-enhanced intracellular delivery of benznidazole for treatment of Trypanosoma cruzi infection. JCI Insight, 2021, 6, .	5.0	5
181	Chagas Disease. Clinics in Perinatology, 2021, 48, 331-342.	2.1	5
182	Nano-Medicines a Hope for Chagas Disease!. Frontiers in Molecular Biosciences, 2021, 8, 655435.	3.5	13
183	Treatment With Suboptimal Dose of Benznidazole Mitigates Immune Response Molecular Pathways in Mice With Chronic Chagas Cardiomyopathy. Frontiers in Cellular and Infection Microbiology, 2021, 11, 692655.	3.9	9
184	Local association of Trypanosoma cruzi chronic infection foci and enteric neuropathic lesions at the tissue micro-domain scale. PLoS Pathogens, 2021, 17, e1009864.	4.7	13
185	A Novel High-Content Screening-Based Method for Anti-Trypanosoma cruzi Drug Discovery Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Stem Cells International, 2021, 2021, 1-12.	2.5	7
186	Drug Target Validation of the Protein Kinase AEK1, Essential for Proliferation, Host Cell Invasion, and Intracellular Replication of the Human Pathogen Trypanosoma cruzi. Microbiology Spectrum, 2021, 9, e0073821.	3.0	8
187	An unusual case of congestive heart failure in the Netherlands. JMM Case Reports, 2018, 5, e005142.	1.3	3
188	Parasites. , 0, , 411-466.		1

#	ARTICLE	IF	CITATIONS
189	Electrocardiographic Abnormalities and Treatment with Benznidazole among Children with Chronic Infection by <i>Trypanosoma cruzi</i> : A Retrospective Cohort Study. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004651.	3.0	13
190	Therapeutic Efficacy of a Subunit Vaccine in Controlling Chronic <i>Trypanosoma cruzi</i> Infection and Chagas Disease Is Enhanced by Glutathione Peroxidase Over-Expression. <i>PLoS ONE</i> , 2015, 10, e0130562.	2.5	19
191	Quantification of Immunoglobulin G against <i>Trypanosoma cruzi</i> in Individuals with Chronic Chagas Disease Treated with Nifurtimox and Evaluated in Prolonged Follow-Up. <i>Korean Journal of Parasitology</i> , 2019, 57, 39-41.	1.3	4
192	Emerging and under-recognized Chagas cardiomyopathy in non-endemic countries. <i>World Journal of Cardiology</i> , 2012, 4, 234.	1.5	4
193	USO DE LA REACCIÓN EN CADENA DE LA POLIMERASA PARA EL CONTROL TERAPÉUTICO DE LA INFECCIÓN CRÓNICA POR <i>Trypanosoma cruzi</i> . <i>Journal of Tropical Pathology</i> , 2015, 44, .	0.2	4
194	Serological response to nifurtimox in adult patients with chronic Chagas disease: An observational comparative study in Argentina. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009801.	3.0	3
195	Identification of a Proteasome-Targeting Arylsulfonamide with Potential for the Treatment of Chagas™ Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0153521.	3.2	11
197	Infectious Emergencies in Dermatology. , 2013, , 19-41.		0
199	Trypanosomiasis and Cardiac Disease. , 2014, , 2407-2419.		0
200	Mykosen und Parasiten. , 2014, , 945-973.		0
201	CARDIAC MAGNETIC RESONANCE IN THE EVALUATION OF FIBROSIS IN CHAGAS™ DISEASE. <i>Brazilian Journal of Medicine and Human Health</i> , 2014, 2, .	0.0	0
202	Antiparasitic Agents. , 0, , 2527-2549.		0
204	Protozoen und Helminthen bei Kindern und Jugendlichen. <i>Springer Reference Medizin</i> , 2019, , 1-32.	0.0	0
205	Determination of Benznidazole in Human Dried Blood Spots by Liquid Chromatography-Mass Spectrometry to Monitor Adherence to <i>Trypanosoma cruzi</i> Infection Treatment in Infants and Children. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 101, 116-122.	1.4	2
206	Achalasia and Chagas™ Disease. , 2020, , 23-28.		0
207	Actualización de la Enfermedad de Chagas desde Atención Primaria. <i>Revista De Investigación Y Educación En Ciencias De La Salud (RIECS)</i> , 2019, 4, 29-46.	0.0	0
208	Chagas Disease: South American Trypanosomiasis. , 2020, , 301-305.		0
209	Protozoen und Helminthen. <i>Springer Reference Medizin</i> , 2020, , 1387-1418.	0.0	0

#	ARTICLE	IF	CITATIONS
210	The Role of Surgery in Treating Parasitic Diseases of the Gastrointestinal Tract from Protozoa. , 2020, , 49-63.		0
211	Parasitic Infections in the Immunocompromised Host: Prevention, Diagnosis, and Management. , 2020, , 323-339.		1
212	Modulation of miR-145-5p and miR-146b-5p levels is linked to reduced parasite load in H9C2 Trypanosoma cruzi infected cardiomyoblasts. Scientific Reports, 2022, 12, 1436.	3.3	8
213	Geospatial Analysis as a Tool to Identify Target Areas for Chagas Disease Education for Healthcare Providers. SSRN Electronic Journal, 0, , .	0.4	0
214	Emergence of Congenital Chagas Disease in Ireland. Pediatric Infectious Disease Journal, 2022, 41, 587-589.	2.0	1
218	Bioactivity of Novel Pyrazole-Thiazolines Scaffolds against Trypanosoma cruzi: Computational Approaches and 3D Spheroid Model on Drug Discovery for Chagas Disease. Pharmaceutics, 2022, 14, 995.	4.5	3
219	Early identification of patients with Chagas disease at risk of developing cardiomyopathy using 2-D speckle tracking strain. IJC Heart and Vasculature, 2022, 41, 101060.	1.1	0
220	Nucleoside triphosphate diphosphohydrolase1 (TcNTPDase-1) gene expression is increased due to heat shock and in infective forms of Trypanosoma cruzi. Parasites and Vectors, 2014, 7, 463.	2.5	0
221	Geospatial analysis as a tool to identify target areas for Chagas disease education for healthcare providers. BMC Infectious Diseases, 2022, 22, .	2.9	0
222	Benznidazole and amiodarone combined treatment attenuates cytoskeletal damage in Trypanosoma cruzi-infected cardiac cells. Frontiers in Cellular and Infection Microbiology, 0, 12, .	3.9	3
223	Transplantation for chagasâ€™ disease: closing the knowledge gap. Current Opinion in Infectious Diseases, 2022, 35, 397-403.	3.1	3
224	Leishmaniasis and Chagas disease: Is there hope in nanotechnology to fight neglected tropical diseases?. Frontiers in Cellular and Infection Microbiology, 0, 12, .	3.9	3
225	Trypanosoma Species (Trypanosomiasis). , 2023, , 1402-1409.e3.		0
226	Use of Leishmania major parasites expressing a recombinant Trypanosoma cruzi antigen as live vaccines against Chagas disease. Frontiers in Microbiology, 0, 13, .	3.5	2
227	Overexpression of TcNTPDase-1 Gene Increases Infectivity in Mice Infected with Trypanosoma cruzi. International Journal of Molecular Sciences, 2022, 23, 14661.	4.1	0
228	Tolerance and Adherence of Patients with Chronic Chagas Disease Treated with Benznidazole. Revista Da Sociedade Brasileira De Medicina Tropical, 0, 56, .	0.9	1
229	Candimine from Hippeastrum escoipense (Amaryllidaceae): Anti-Trypanosoma cruzi activity and synergistic effect with benznidazole. Phytomedicine, 2023, 114, 154788.	5.3	3
230	Trypanosoma cruzi DTU II coinfection with bacteria producing prolonged cutaneous lesion in a healthy young male. Revista Do Instituto De Medicina Tropical De Sao Paulo, 0, 65, .	1.1	0

#	ARTICLE	IF	CITATIONS
231	Treatment with benznidazole and pentoxifylline regulates microRNA transcriptomic profile in a murine model of Chagas chronic cardiomyopathy. PLoS Neglected Tropical Diseases, 2023, 17, e0011223.	3.0	4
232	A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma. International Journal of Cancer, 0, , .	5.1	1
233	The evolution of electrocardiographic abnormalities in the elderly with Chagas disease during 14 years of follow-up: The Bambui Cohort Study of Aging. PLoS Neglected Tropical Diseases, 2023, 17, e0011419.	3.0	1
234	Metallic Nanoparticles and Core-Shell Nanosystems in the Treatment, Diagnosis, and Prevention of Parasitic Diseases. Pathogens, 2023, 12, 838.	2.8	5